搜索医生

Saranya Chumsri, M.D.

  1. Oncologist
预约门诊

出版物

  1. Haddad TC, Suman VJ, Giridhar KV, Sideras K, Northfelt DW, Ernst BJ, O'Sullivan CC, Singh RJ, Desta Z, Peethambaram PP, Hobday TJ, Chumsri S, Leon-Ferre RA, Ruddy KJ, Yadav S, Taraba JL, Goodnature B, Goetz MP, Wang L, Ingle JN. Anastrozole dose escalation for optimal estrogen suppression in postmenopausal early-stage breast cancer: A prospective trial. Clin Cancer Res. 2024 May 16 [Epub ahead of print]
    View PubMed
  2. Martins-Branco D, Kassapian M, Debien V, Caparica R, Eiger D, Dafni U, Andriakopoulou C, El-Abed S, Ellard SL, Izquierdo M, Vicente M, Chumsri S, Piccart-Gebhart M, Moreno-Aspitia A, Knop AS, Lombard J, de Azambuja E. The impact of erythropoiesis-stimulating agents administration concomitantly with adjuvant anti-HER2 treatments on the outcomes of patients with early breast cancer: a sub-analysis of the ALTTO study. Breast Cancer Res Treat. 2024 Feb; 203 (3):497-509 Epub 2023 Nov 08
    View PubMed
  3. Chumsri S. Serum hormone concentrations and individualisation of breast cancer prevention. Lancet Oncol. 2024 Jan; 25 (1):8-9
    View PubMed
  4. Wang KL, Hall MR, Chumsri S, Sokumbi O. Soft pink plaques at site of breast cancer vaccination: challenge. American Journal of Dermatopathology. 2024; 46 (5):E29-30
  5. Caldera F, Farraye FA, Necela BM, Cogen D, Saha S, Wald A, Daoud ND, Chun K, Grimes I, Lutz M, Van Helden SR, Swift MD, Virk A, Bharucha AE, Patel TC, Gores GJ, Chumsri S, Hayney MS, Knutson KL. Higher Cell-Mediated Immune Responses in Patients With Inflammatory Bowel Disease on Anti-TNF Therapy After COVID-19 Vaccination. Inflamm Bowel Dis. 2023 Aug 01; 29(8):1202-1209.
  6. Chumsri S. Advancing outcomes of metastatic HER2-positive breast cancer. Lancet 2023 May 27; 401 (10390):1746-1747 Epub 2023 Apr 20
    View PubMed
  7. Carter JM, Chumsri S, Hinerfeld DA, Ma Y, Wang X, Zahrieh D, Hillman DW, Tenner KS, Kachergus JM, Brauer HA, Warren SE, Henderson D, Shi J, Liu Y, Joensuu H, Lindman H, Leon-Ferre RA, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Knutson KL, Goetz MP, Perez EA, Thompson EA. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. Nat Commun. 2023 Apr 18; 14 (1):2215
    View PubMed
  8. Kaplan JL, Turker I, Chumsri S, Gabriel E. Abscopal Effect Following Cryoablation in a Patient with Metastatic Breast Cancer. Front Biosci (Schol Ed). 2023 Jan 16; 15 (1):2
    View PubMed
  9. Sammons S, Elliott A, Barroso-Sousa R, Chumsri S, Tan AR, Sledge GW Jr, Tolaney SM, Torres ETR. Concurrent predictors of an immune responsive tumor microenvironment within tumor mutational burden-high breast cancer. Front Oncol. 2023; 13:1235902 Epub 2023 Aug 11
    View PubMed
  10. An Z, Figueroa-Parra G, Zhou X, Li Y, Jaquith J, McCarthy-Fruin K, Sletten J, Warrington KJ, Weyand C, Crowson CS, Chumsri S, Knutson KL, Sanchez-Rodriguez A, Thanarajasingam U, Duarte-Garcia A, Zeng H. Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients. Front Immunol. 2023; 14:1224702 Epub 2023 July 31
    View PubMed
  11. Nader-Marta G, Debien V, Eiger D, Tsourti Z, Caparica R, Kassapian M, Napoleone S, Hultsch S, Korde L, Wang Y, Chumsri S, Pritchard KI, Untch M, Bellet-Ezquerra M, Dornelles Rosa D, Moreno-Aspitia A, Piccart M, Dafni U, de Azambuja E. Outcomes of patients with small and node-negative HER2-positive early breast cancer treated with adjuvant chemotherapy and anti-HER2 therapy-a sub-analysis of the ALTTO study. Br J Cancer. 2022 Nov; 127 (10):1799-1807 Epub 2022 Sept 01
    View PubMed
  12. Maimone S, Robinson KA, Advani PP, Li Z, Gococo-Benore DA, Qosja N, Ashai AM, Mummareddy A, Chumsri S. Limiting Screening Mammography Recalls for Vaccine-Induced Adenopathy, a Single Institution Experience. Acad Radiol. 2022 Oct; 29 (10):1480-1485 Epub 2022 Jan 26
    View PubMed
  13. Sammons S, Raskina K, Danziger N, Alder L, Schrock AB, Venstrom JM, Knutson KL, Thompson EA, McGregor K, Sokol E, Chumsri S. APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. JCO Precis Oncol. 2022 Oct; 6:e2200149.
    View PubMed
  14. Agostinetto E, Ameye L, Martel S, Aftimos P, Ponde N, Maurer C, El-Abed S, Wang Y, Vicente M, Chumsri S, Bliss J, Kroep J, Colleoni M, Petrelli F, Del Mastro L, Moreno-Aspitia A, Piccart M, Paesmans M, de Azambuja E, Lambertini M. PREDICT underestimates survival of patients with HER2-positive early-stage breast cancer. NPJ Breast Cancer. 2022 Jul 20; 8 (1):87 Epub 2022 July 20
    View PubMed
  15. Gardner KP, Cristofanilli M, Chumsri S, Lapidus R, Tang CM, Raghavakaimal A, Adams DL. Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer. Int J Mol Sci. 2022 Jun 30; 23 (13) Epub 2022 June 30
    View PubMed
  16. Seneviratne D, Advani P, Trifiletti DM, Chumsri S, Beltran CJ, Bush AF, Vallow LA. Exploring the Biological and Physical Basis of Boron Neutron Capture Therapy (BNCT) as a Promising Treatment Frontier in Breast Cancer. Cancers (Basel). 2022 Jun 18; 14 (12) Epub 2022 June 18
    View PubMed
  17. Chumsri S, Li Z, Serie DJ, Norton N, Mashadi-Hossein A, Tenner K, Brauer HA, Warren S, Danaher P, Colon-Otero G, Partridge AH, Carey LA, Hilbers F, Van Dooren V, Holmes E, Di Cosimo S, Werner O, Huober JB, Dueck AC, Sotiriou C, Saura C, Moreno-Aspitia A, Knutson KL, Perez EA, Thompson EA. Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials. NPJ Breast Cancer. 2022 May 24; 8(1):68.
    View PubMed
  18. Raghavakaimal A, Cristofanilli M, Tang CM, Alpaugh RK, Gardner KP, Chumsri S, Adams DL. CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome. Breast Cancer Res. 2022 May 23; 24 (1):35
    View PubMed
  19. Chumsri S, Advani PP, Pai TS, Li Z, Mummareddy A, Acampora M, Reynolds GA, Wylie N, Boyle AW, Lou Y, Mody K, Moreno-Aspitia A, Swift MD, Virk A, Bharucha AE, Marquez CP, Patel TC, Gores GJ, Knutson KL. Humoral Responses After SARS-CoV-2 mRNA Vaccination and Breakthrough Infection in Cancer Patients. Mayo Clin Proc Innov Qual Outcomes. 2022 Apr; 6 (2):120-125 Epub 2021 Dec 13
    View PubMed
  20. Advani P, Chumsri S, Pai T, Li Z, Sharma A, Parent E. Temporal metabolic response to mRNA COVID-19 vaccinations in oncology patients. Ann Nucl Med. 2021 Nov; 35 (11):1264-1269 Epub 2021 Aug 31
    View PubMed
  21. Robinson KA, Maimone S, Gococo-Benore DA, Li Z, Advani PP, Chumsri S. Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination. JAMA Oncol. 2021 Sep 1; 7 (9):1395-1397
    View PubMed
  22. Pai TS, Rojas C, Wasserman MC, Parent EE, Cornell L, Chumsri S. Asymptomatic coronavirus disease 2019 mimicking metastatic breast cancer on positron emission tomography/computed tomography imaging. Radiol Case Rep. 2021 Aug; 16 (8):2226-2230 Epub 2021 June 13
    View PubMed
  23. Lambertini M, Agbor-Tarh D, Metzger-Filho O, Ponde NF, Poggio F, Hilbers FS, Korde LA, Chumsri S, Werner O, Del Mastro L, Caparica R, Moebus V, Moreno-Aspitia A, Piccart MJ, de Azambuja E. Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial. ESMO Open. 2020 Nov; 5 (6):e000979
    View PubMed
  24. Asleh K, Brauer HA, Sullivan A, Lauttia S, Lindman H, Nielsen TO, Joensuu H, Thompson EA, Chumsri S. Predictive Biomarkers for Adjuvant Capecitabine Benefit in Early-Stage Triple-Negative Breast Cancer in the FinXX Clinical Trial. Clin Cancer Res. 2020 Jun 1; 26 (11):2603-2614 Epub 2020 Jan 31
    View PubMed
  25. Chumsri S, Sokol ES, Soyano-Muller AE, Parrondo RD, Reynolds GA, Nassar A, Thompson EA. Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature. J Natl Compr Canc Netw. 2020 May; 18 (5):517-521
    View PubMed
  26. Eiger D, Ponde NF, Agbor-Tarh D, Moreno-Aspitia A, Piccart M, Hilbers FS, Werner O, Chumsri S, Dueck A, Kroep JR, Gomez H, Lang I, Rodeheffer RJ, Ewer MS, Suter T, de Azambuja E. Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. Br J Cancer. 2020 May; 122 (10):1453-1460 Epub 2020 Mar 16
    View PubMed
  27. Knutson KL, Block MS, Norton N, Erskine CL, Hobday TJ, Dietz AB, Padley D, Gustafson MP, Puglisi-Knutson D, Mangskau TK, Chumsri S, Dueck AC, Karyampudi L, Wilson G, Degnim AC. Rapid Generation of Sustainable HER2-specific T-cell Immunity in Patients with HER2 Breast Cancer using a Degenerate HLA Class II Epitope Vaccine. Clin Cancer Res. 2020 Mar 1; 26 (5):1045-1053 Epub 2019 Nov 22
    View PubMed
  28. Chumsri S, Thompson EA. Carryover effects of aromatase inhibitors in prevention. Lancet 2020 Jan 11; 395 (10218):91-92 Epub 2019 Dec 13
    View PubMed
  29. Chumsri S, Li Z, Serie DJ, Mashadi-Hossein A, Colon-Otero G, Song N, Pogue-Geile KL, Gavin PG, Paik S, Moreno-Aspitia A, Perez EA, Thompson EA. Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31. J Clin Oncol. 2019 Dec 10; 37 (35):3425-3435 Epub 2019 Oct 17
    View PubMed
  30. Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E. Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial. Breast Cancer Res Treat. 2019 Aug; 177 (1):103-114 Epub 2019 May 27
    View PubMed
  31. Chumsri S, Serie DJ, Li Z, Pogue-Geile KL, Soyano-Muller AE, Mashadi-Hossein A, Warren S, Lou Y, Colon-Otero G, Knutson KL, Perez EA, Moreno-Aspitia A, Thompson EA. Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) Trials. Clin Cancer Res. 2019 Jul 15; 25 (14):4422-4430 Epub 2019 Feb 26
    View PubMed
  32. Soyano AE, Dholaria B, Marin-Acevedo JA, Diehl N, Hodge D, Luo Y, Manochakian R, Chumsri S, Adjei A, Knutson KL, Lou Y. Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. J Immunother Cancer. 2018 Nov 23; 6 (1):129
    View PubMed
  33. Chumsri S, Sperinde J, Liu H, Gligorov J, Spano JP, Antoine M, Moreno Aspitia A, Tan W, Winslow J, Petropoulos CJ, Chenna A, Bates M, Weidler JM, Huang W, Dueck A, Perez EA. High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance). Clin Cancer Res. 2018 Jul 1; 24 (13):3053-3058 Epub 2018 Mar 12
    View PubMed
  34. Marin-Acevedo JA, Dholaria B, Soyano AE, Knutson KL, Chumsri S, Lou Y. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018 Mar 15; 11 (1):39
    View PubMed
  35. Soyano AE, Reynolds G, Moreno-Aspitia A, Chumsri S. Rifaximin for Pertuzumab-Related GI Toxicities. Front Oncol. 2017; 7:168 Epub 2017 Aug 08
    View PubMed
  36. Ross JS, Gay LM, Wang K, Ali SM, Chumsri S, Elvin JA, Bose R, Vergilio JA, Suh J, Yelensky R, Lipson D, Chmielecki J, Waintraub S, Leyland-Jones B, Miller VA, Stephens PJ. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies. Cancer. 2016 Sep 1; 122 (17):2654-62 Epub 2016 June 10
    View PubMed
  37. Adams DL, Adams DK, Alpaugh RK, Cristofanilli M, Martin SS, Chumsri S, Tang CM, Marks JR. Circulating Cancer-Associated Macrophage-Like Cells Differentiate Malignant Breast Cancer and Benign Breast Conditions. Cancer Epidemiol Biomarkers Prev. 2016 Jul; 25 (7):1037-42 Epub 2016 May 17
    View PubMed
  38. Kesmodel SB, Goloubeva OG, Rosenblatt PY, Heiss B, Bellavance EC, Chumsri S, Bao T, Thompson J, Nightingale G, Tait NS, Nichols EM, Feigenberg SJ, Tkaczuk KH. Patient-reported Adherence to Adjuvant Aromatase Inhibitor Therapy Using the Morisky Medication Adherence Scale: An Evaluation of Predictors. Am J Clin Oncol. 2016 Jun 17;
    View PubMed
  39. Adams DL, Adams DK, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK. Mitosis in circulating tumor cells stratifies highly aggressive breast carcinomas. Breast Cancer Res. 2016 May 4; 18 (1):44 Epub 2016 May 04
    View PubMed
  40. Tomita Y, Lee MJ, Lee S, Tomita S, Chumsri S, Cruickshank S, Ordentlich P, Trepel JB. The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: Correlative analysis of ENCORE 301, a randomized, placebo-controlled phase II trial of exemestane with or without entinostat. Oncoimmunology. 2016; 5 (11):e1219008 Epub 2016 Aug 31
    View PubMed
  41. Tomita Y, Lee MJ, Lee S, Tomita S, Chumsri S, Cruickshank S, Ordentlich P, Trepel JB. The interplay of epigenetic therapy and immunity in locally recurrent or metastatic estrogen receptor-positive breast cancer: correlative analysis of encore 301, a randomized, placebo-controlled phase ii trial of exemestane with or without entinostat Oncoimmunology. 2016; 5: (11)e1219008.
  42. Adams DL, Alpaugh RK, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Adams DK, Makarova OV, Zhu P, Li S, Tang CM, Stefansson S. Precision Microfilters as an all in one System for Multiplex Analysis of Circulating Tumor Cells. RSC Adv. 2016; 6 (8):6405-6414 Epub 2016 Jan 11
    View PubMed
  43. Choe M, Brusgard JL, Chumsri S, Bhandary L, Zhao XF, Lu S, Goloubeva OG, Polster BM, Fiskum GM, Girnun GD, Kim MS, Passaniti A. The RUNX2 Transcription Factor Negatively Regulates SIRT6 Expression to Alter Glucose Metabolism in Breast Cancer Cells. J Cell Biochem. 2015 Oct; 116: (10)2210-26.
    View PubMed
  44. Brusgard JL, Choe M, Chumsri S, Renoud K, MacKerell AD Jr, Sudol M, Passaniti A. RUNX2 and TAZ-dependent signaling pathways regulate soluble E-Cadherin levels and tumorsphere formation in breast cancer cells. Oncotarget. 2015 Sep 29; 6 (29):28132-50
    View PubMed
  45. Chumsri S, Weidler J, Ali S, Balasubramanian S, Wallweber G, DeFazio-Eli L, Chenna A, Huang W, DeRidder A, Goicocheal L, Perez EA. Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation. J Natl Compr Canc Netw. 2015 Sep; 13 (9):1066-70
    View PubMed
  46. Schech AJ, Shah P, Yu S, Sabnis GJ, Goloubeva O, Rosenblatt P, Kazi A, Chumsri S, Brodie A. Histone deacetylase inhibitor entinostat in combination with a retinoid downregulates her2 and reduces the tumor initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2015 Aug; 152(3):499-508.
    View PubMed
  47. Kalsi R, Feigenberg S, Kwok Y, Tkaczuk K, Mehta M, Chumsri S. Brain metastasis and response to ado-trastuzumab emtansine: a case report and literature review. Clin Breast Cancer. 2015 Apr; 15 (2):e163-6 Epub 2014 Oct 19
    View PubMed
  48. Advani P, Cornell L, Chumsri S, Moreno-Aspitia A. Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. Breast Cancer (Dove Med Press). 2015; 7:321-35 Epub 2015 Sept 22
    View PubMed
  49. Adams DL, Stefansson S, Haudenschild C, Martin SS, Charpentier M, Chumsri S, Cristofanilli M, Tang CM, Alpaugh RK. Cytometric characterization of Circulating Tumor Cells Captured by microfiltration and their correlation to the cellsearch(R) CTC test. Cytometry Part A. 2015; 87(2):137-44.
  50. Chumsri S. Clinical utilities of aromatase inhibitors in breast cancer. Int J Womens Health. 2015; 7:493-9 Epub 2015 May 06
    View PubMed
  51. Suzuki I, Chakkabat P, Goicochea L, Campassi C, Chumsri S. Lymphoepithelioma-like carcinoma of the breast presenting as breast abscess. World J Clin Oncol. 2014 Dec 10; 5: (5)1107-12.
    View PubMed
  52. Guha P, Bandyopadhyaya G, Polumuri SK, Chumsri S, Gade P, Kalvakolanu DV, Ahmed H. Nicotine promotes apoptosis resistance of breast cancer cells and enrichment of side population cells with cancer stem cell-like properties via a signaling cascade involving galectin-3, alpha9 nicotinic acetylcholine receptor and STAT3. Breast Cancer Res Treat. 2014 May; 145: (1)5-22.
    View PubMed
  53. Singh SN, Zhu Y, Chumsri S, Kesmodel S, Gilliam BL, Riedel DJ. Outcomes and chemotherapy-related toxicity in HIV-infected patients with breast cancer. Clin Breast Cancer. 2014 Apr; 14: (2)e53-9.
    View PubMed
  54. Chumsri S, Schech A, Chakkabat C, Sabnis G, Brodie A. Advances in mechanisms of resistance to aromatase inhibitors. Expert Rev Anticancer Ther. 2014 Apr; 14: (4)381-93.
    View PubMed
  55. Adams DL, Martin SS, Alpaugh RK, Charpentier M, Tsai S, Bergan RC, Ogden IM, Catalona W, Chumsri S, Tang CM, Cristofanilli M. Circulating giant macrophages as a potential biomarker of solid tumors. Proc Natl Acad Sci U S A. 2014 Mar 04; 111: (9)3514-9.
    View PubMed
  56. Bao T, Cai L, Snyder C, Betts K, Tarpinian K, Gould J, Jeter S, Medeiros M, Chumsri S, Bardia A, Tan M, Singh H, Tkaczuk KH, Stearns V. Patient-reported outcomes in women with breast cancer enrolled in a dual-center, double-blind, randomized controlled trial assessing the effect of acupuncture in reducing aromatase inhibitor-induced musculoskeletal symptoms. Cancer. 2014 Feb 01; 120: (3)381-9.
    View PubMed
  57. Chumsri S, Sabnis G, Tkaczuk K, Brodie A. mTOR inhibitors: changing landscape of endocrine-resistant breast cancer. Future Oncol. 2014 Feb; 10: (3)443-56.
    View PubMed
  58. Kazi AA, Gilani RA, Schech AJ, Chumsri S, Sabnis G, Shah P, Goloubeva O, Kronsberg S, Brodie AH. Nonhypoxic regulation and role of hypoxia-inducible factor 1 in aromatase inhibitor resistant breast cancer. Breast Cancer Res. 2014; 16(1):R15. Epub 2014 Jan 29.
    View PubMed
  59. Bhatnagar B, Gilmore S, Goloubeva O, Pelser C, Medeiros M, Chumsri S, Tkaczuk K, Edelman M, Bao T. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014; 3:366.
    View PubMed
  60. Kesmodel SB, Sabnis GJ, Chumsri S, Brodie AM. Combined cancer therapy: strategies to overcome acquired aromatase inhibitor resistance. Curr Pharm Des. 2014; 20: (42)6575-83.
    View PubMed
  61. Adams DL, Zhu P, Makarova OV, Martin SS, Charpentier M, Chumsri S, Li S, Amstutz P, Tang CM. The systematic study of circulating tumor cell isolation using lithographic microfilters. RSC Adv. 2014; 9:4334-4342.
    View PubMed
  62. Mahmood U, Hanlon AL, Koshy M, Buras R, Chumsri S, Tkaczuk KH, Cheston SB, Regine WF, Feigenberg SJ. Increasing national mastectomy rates for the treatment of early stage breast cancer. Ann Surg Oncol. 2013 May; 20(5):1436-43. Epub 2012 Nov 08.
    View PubMed
  63. Bao T, Cai L, Giles JT, Gould J, Tarpinian K, Betts K, Medeiros M, Jeter S, Tait N, Chumsri S, Armstrong DK, Tan M, Folkerd E, Dowsett M, Singh H, Tkaczuk K, Stearns V. A dual-center randomized controlled double blind trial assessing the effect of acupuncture in reducing musculoskeletal symptoms in breast cancer patients taking aromatase inhibitors. Breast Cancer Res Treat. 2013 Feb; 138(1):167-74. Epub 2013 Feb 08.
    View PubMed
  64. Chumsri S, Shah P. Radiation Resistance of Cancer Stem Cells as an Obstacle in Cancer Therapy. Mol Cell Pharmacol. 2013; 5(1):39-49.
  65. Sheth NU, Gilmore S, Bauer K, Chumsri S. The effect of atazanavir on doxorubicin pharmacokinetics: A case report. JHOP. 2013; 3(2):1.
  66. Gilani RA, Kazi AA, Shah P, Schech AJ, Chumsri S, Sabnis G, Jaiswal AK, Brodie AH. The importance of HER2 signaling in the tumor-initiating cell population in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2012 Oct; 135(3):681-92. Epub 2012 Aug 10.
    View PubMed
  67. Mahmood U, Morris C, Neuner G, Koshy M, Kesmodel S, Buras R, Chumsri S, Bao T, Tkaczuk K, Feigenberg S. Similar survival with breast conservation therapy or mastectomy in the management of young women with early-stage breast cancer. Int J Radiat Oncol Biol Phys. 2012 Aug 1; 83(5):1387-93. Epub 2012 Jan 31.
    View PubMed
  68. Tobin LA, Robert C, Nagaria P, Chumsri S, Twaddell W, Ioffe OB, Greco GE, Brodie AH, Tomkinson AE, Rassool FV. Targeting abnormal DNA repair in therapy-resistant breast cancers. Mol Cancer Res. 2012 Jan; 10(1):96-107. Epub 2011 Nov 23.
    View PubMed
  69. Eades G, Yao Y, Yang M, Zhang Y, Chumsri S, Zhou Q. miR-200a regulates SIRT1 expression and epithelial to mesenchymal transition (EMT)-like transformation in mammary epithelial cells. J Biol Chem. 2011 Jul 22; 286(29):25992-6002. Epub 2011 May 19.
    View PubMed
  70. Chumsri S, Sabnis GJ, Howes T, Brodie AM. Aromatase inhibitors and xenograft studies. Steroids. 2011 Jul; 76(8):730-5. Epub 2011 Mar 21.
    View PubMed
  71. Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol. 2011 May; 125(1-2):13-22. Epub 2011 Feb 16.
    View PubMed
  72. Sabnis GJ, Goloubeva O, Chumsri S, Nguyen N, Sukumar S, Brodie AM. Functional activation of the estrogen receptor-alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER-negative tumors to letrozole. Cancer Res. 2011 Mar 1; 71(5):1893-903. Epub 2011 Jan 18.
    View PubMed
  73. Brodie AMH, Chumsri S, Sukumar S, Sabnis G. Extending aromatase inhibitor sensitivity in hormone resistant breast cancer. Hormone Molecular Biology and Clinical Investigation. 2011; 5(2):97-103.
  74. Linn DE, Yang X, Sun F, Xie Y, Chen H, Jiang R, Chen H, Chumsri S, Burger AM, Qiu Y. A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Genes Cancer. 2010 Sep; 1 (9):908-16
    View PubMed
  75. Nakanishi T, Chumsri S, Khakpour N, Brodie AH, Leyland-Jones B, Hamburger AW, Ross DD, Burger AM. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br J Cancer. 2010 Mar 2; 102(5):815-26. Epub 2010 Feb 09.
    View PubMed
  76. Chumsri S, Jeter S, Jacobs LK, Nassar H, Armstrong DK, Emens LA, Fetting JH, Lange JR, Riley C, Tsangaris TN, Wolff AC, Zellars R, Zhang Z, Stearns V. Pathologic complete response to preoperative sequential doxorubicin/cyclophosphamide and single-agent taxane with or without trastuzumab in stage II/III HER2-positive breast cancer. Clin Breast Cancer. 2010 Feb; 10(1):40-5.
    View PubMed
  77. Chumsri S, Burger AM. Cancer stem cell targeted agents: therapeutic approaches and consequences. Curr Opin Mol Ther. 2008 Aug; 10(4):323-33.
    View PubMed
  78. Hughes L, Malone C, Chumsri S, Burger AM, McDonnell S. Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity. Clin Exp Metastasis. 2008; 25(5):549-57. Epub 2008 Apr 02.
    View PubMed
  79. Chumsri S, Matsui W, Burger AM. Therapeutic implications of leukemic stem cell pathways. Clin Cancer Res. 2007 Nov 15; 13(22 Pt 1):6549-54.
    View PubMed
  80. Chumsri S, Phatak P, Edelman MJ, Khakpour N, Hamburger AW, Burger AM. Cancer stem cells and individualized therapy. Cancer Genomics Proteomics. 2007 May-Jun; 4(3):165-74.
    View PubMed
  81. Chumsri S, Zimrin AB, Gibble JW, Hess JR. Transfusion medicine illustrated: centrolobular lung edema in probable transfusion-related acute lung injury. Transfusion. 2007 Feb; 47(2):183.
    View PubMed
  82. Alexiev BA, Wang W, Ning Y, Chumsri S, Gojo I, Rodgers WH, Stass SA, Zhao XF. Myeloid sarcomas: a histologic, immunohistochemical, and cytogenetic study. Diagn Pathol. 2007; 2:42. Epub 2007 Oct 31.
    View PubMed
PST-20217235